Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial

Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial

BackgroundEffective therapies for pulmonary fibrosis caused by coronavirus disease (COVID-19) and other etiologies are lacking. Our previous studies demonstrated that Fuzheng Huayu tablet (FZHY), a traditional Chinese medicine known for its anti-liver fibrotic properties, can improve lung function i...

Full description

Saved in:
Bibliographic Details
Main Authors: Fei Jing, Wei Wang, Jia Ke, Tingrong Huang, Bo Jiang, Qiwu Qiu, Jihan Huang, Songhua Zhan, Wei Zhang, Hui Wu, Wen Su, Jiawen Feng, Yuan Peng, Zhimin Zhao, Feng Xing, Chenghai Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
Fuzheng Huayu tablet
pulmonary fibrosis
pulmonary function
COVID-19
randomized controlled trial
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1508276/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1508276/full

Similar Items